

## Special Issue

# Drug Combination Therapy of Glioblastoma

### Message from the Guest Editors

Glioblastoma is still the most devastating cancer of the central nervous system, and standard treatment options are mostly palliative. In the last decade, many monotherapeutic strategies have failed in clinical trials; therefore, there is an urgent need to develop novel treatment schemes. Combined therapy in glioma seems to be a promising solution, but for now, it remains a challenging endeavor rather than a real clinical treatment option. Glioblastoma is a complex disease presenting features such as inter-/intratumor heterogeneity, altered metabolism, high proliferation rate, hypoxic niches, drug resistance, immunosuppression, and self-renewal. The design of efficient polypharmacotherapy requires, on one hand, ensuring synergistic drug action on strategic targets in tumors, and on the other, facilitating drug transport across the blood–brain barrier, delivery to glioma cells, internalization and controlled release, and maintenance of a stable and controlled blood drug level. This Special Issue will highlight the role of combination therapy of glioblastoma, its preclinical aspects, limitations, potential advantages/disadvantages, and current status.

### Guest Editors

Prof. Dr. Ewa Obuchowicz

Department of Pharmacology, Faculty of Medical Sciences in Katowice,  
Medical University of Silesia, Katowice, Poland

Dr. Anna Bielecka-Wajdman

Department of Pharmacology, Faculty of Medical Sciences in Katowice,  
Medical University of Silesia, Katowice, Poland

### Deadline for manuscript submissions

closed (20 December 2024)



## Cancers

an Open Access Journal  
by MDPI

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/146566](https://mdpi.com/si/146566)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)